

In the Specification:

The paragraph starting at page 20, line 20 has been amended as follows:

--Murine MAbs to HERCEPTIN® (such as AMER5) ~~was~~ were produced and characterized by standard methods. HERCEPTIN® expressed and purified from CHO cells was used to immunize mice. Spleen cells from immunized mice were fused with myeloma cells, the hybrid cells were selected, cloned and screened for antibodies which specifically recognize HERCEPTIN®.--

The following paragraph has been inserted on page 29, following line 6:

--Deposit of Materials

The following hybridoma cell line has been deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 USA (ATCC):

Antibody Designation	ATCC No.	Deposit Date
7C2	ATCC HB-12215	Oct. 17, 1996

This deposit was made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of the pertinent U.S. patent, assures permanent and unrestricted availability of the progeny of the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14 with particular reference to 886 OG 638).--